Li T - Search Results

1

Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM. Wang WP, et al. Among authors: li mm, li t. J Pharmacol Exp Ther. 2015 Aug;354(2):131-41. doi: 10.1124/jpet.115.225631. Epub 2015 May 28. J Pharmacol Exp Ther. 2015. PMID: 26022002 Free PMC article.

2

Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors.

Xiao W, Li T, Bononi FC, Lac D, Kekessie IA, Liu Y, Sanchez E, Mazloom A, Ma AH, Lin J, Tran J, Yang K, Lam KS, Liu R. Xiao W, et al. Among authors: li t. EJNMMI Res. 2016 Dec;6(1):18. doi: 10.1186/s13550-016-0165-z. Epub 2016 Feb 27. EJNMMI Res. 2016. PMID: 26922417 Free PMC article.

3

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Lin TY, et al. Among authors: li t, li y. Biomaterials. 2016 Oct;104:339-51. doi: 10.1016/j.biomaterials.2016.07.026. Epub 2016 Jul 22. Biomaterials. 2016. PMID: 27479049 Free PMC article.

4

Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.

Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Pan A, et al. Among authors: li t, li y. Nanotechnology. 2016 Oct 21;27(42):425103. doi: 10.1088/0957-4484/27/42/425103. Epub 2016 Sep 19. Nanotechnology. 2016. PMID: 27640312 Free PMC article.

5

High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.

Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. Xiao W, et al. Among authors: li t, li q. J Hematol Oncol. 2019 Jun 10;12(1):56. doi: 10.1186/s13045-019-0740-7. J Hematol Oncol. 2019. PMID: 31182116 Free PMC article.

6

Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer.

Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. Xiao W, et al. Among authors: li t, li q. J Hematol Oncol. 2019 Jul 26;12(1):83. doi: 10.1186/s13045-019-0764-z. J Hematol Oncol. 2019. PMID: 31349855 Free PMC article.

7

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.

Chen JA, Huynh JC, Wu CY, Yu AM, Matsukuma K, Semrad TJ, Gandara DR, Li T, Riess JW, Tam K, Mack PC, Martinez A, Mahaffey N, Kelly KL, Kim EJ. Chen JA, et al. Among authors: li t. Cancer Chemother Pharmacol. 2022 Sep;90(3):217-228. doi: 10.1007/s00280-022-04457-9. Epub 2022 Jul 30. Cancer Chemother Pharmacol. 2022. PMID: 35907014 Free PMC article. Clinical Trial.

8

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Gandara DR, et al. Among authors: li t. Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18. Clin Lung Cancer. 2015. PMID: 25838158 Free PMC article.

9

Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations.

Ma W, Gong J, Shan J, Lewis D, Xiao W, Moore EH, Zhang Y, Hung J, Mans NZ, Wei S, Welborn J, Stollenwerk NS, Lam KS, Li T. Ma W, et al. Among authors: li t. JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.18.00076. JCO Precis Oncol. 2018. PMID: 35135138 No abstract available.

10

Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.

Ma W, Wei S, Li Q, Zeng J, Xiao W, Zhou C, Yoneda KY, Zeki AA, Li T. Ma W, et al. Among authors: li t, li q. Mol Cancer Ther. 2024 May 2;23(5):700-710. doi: 10.1158/1535-7163.MCT-23-0458. Mol Cancer Ther. 2024. PMID: 38237027

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36,984 results

Search Page